Trials / Unknown
UnknownNCT06140082
Study on the Association of GSTP1 and Other Gene Polymorphisms With Platinum-induced Myelosuppression
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 477 (estimated)
- Sponsor
- LI YAN · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study intends to design a retrospective and prospective, cohort study to explore the association between genetic polymorphism of GSTP1 A313G rs1695 or others and adverse effects of platinum drugs, aiming to explore the risk factors of myelosuppression caused by platinum drugs, and provide data support for optimizing anti-tumor chemotherapy regimen, improve medication safety and improve the compliance of chemotherapy in patients.
Detailed description
Patients with pulmonary malignant tumors receiving platinum-containing chemotherapy regimen were included in the retrospective and prospective bidirectional cohort study to collect the basic information of the subjects, including gender, age, smoking history, primary site, basic liver and kidney function, chemotherapy regimen, etc. The polymorphisms of glutathione S transferase (GSTP1 A313G) were detected by Sanger dideoxy termination sequencing. To study the risk factors related to myelosuppression during chemotherapy, and to preliminarily explore the characteristics of myelosuppression caused by combination chemotherapy with platinum.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | GSTP1 A313G （AA） | Patients with pulmonary malignant tumors receiving platinum-containing chemotherapy regimen were included in the retrospective and prospective bidirectional cohort study to collect the basic information of the subjects, including gender, age, smoking history, primary site, basic liver and kidney function, chemotherapy regimen, etc. The polymorphisms of glutathione S transferase (GSTP1 A313G) were detected by Sanger dideoxy termination sequencing. The wild type (AA) and mutant type (AG/GG) were divided into two groups. |
Timeline
- Start date
- 2023-12-01
- Primary completion
- 2025-12-01
- Completion
- 2025-12-30
- First posted
- 2023-11-18
- Last updated
- 2023-11-18
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06140082. Inclusion in this directory is not an endorsement.